Form 4: RA Capital Director Granted VOR Biopharma Stock Options

A director affiliated with RA Capital Management received 60,000 stock options in Vor Biopharma Inc. as part of non-employee compensation.

Summary

• RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Rajeev Shah, reported the grant of 60,000 stock options in Vor Biopharma Inc.
• The options were granted to Sarah Reed, General Counsel of RA Capital Management, L.P., who serves on Vor Biopharma's board of directors.
• The options have an exercise price of $1.98 per share and an expiration date of September 7, 2035.
• Vesting occurs in 36 equal monthly installments, commencing on September 8, 2025, contingent on Ms. Reed's continued service.
• Ms. Reed holds these options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., with proceeds offsetting advisory fees owed to RA Capital Management, L.P.

Sentiment

Score: 7

Explanation: The filing reports a standard compensation event for a director, aligning interests with shareholders. It's a neutral to slightly positive signal of continued board engagement, but not a major operational or financial announcement.

Positives

• Granting of stock options to a non-employee director aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from a key director affiliated with a significant investor.

Risks

• The value of the options is dependent on the future stock price of Vor Biopharma Inc. exceeding the exercise price of $1.98.
• Vesting is contingent on continued service, meaning the options could be forfeited if Ms. Reed's service ceases.

Future Outlook

The options vest over 36 months starting September 8, 2025, indicating an expectation of continued long-term service from the director.

Management Comments

• RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Under Ms. Reed's arrangement with the Adviser, Ms. Reed holds the option for the benefit of the Fund and the Nexus Fund. Ms. Reed is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
• Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

Industry Context

Granting stock options to non-employee directors is a common practice in the biopharmaceutical industry and other sectors to attract and retain experienced board members, aligning their incentives with the company's long-term performance. RA Capital Management is a prominent healthcare investment firm, and its representatives often hold board seats in portfolio companies like Vor Biopharma.

Comparison to Industry Standards

• The grant of 60,000 stock options to a non-employee director is within the typical range for early to mid-stage biopharma companies, comparable to grants seen at companies for similar board roles, though specific values vary based on company stage, market capitalization, and individual director responsibilities.
• An exercise price of $1.98, which is likely the market price on the grant date, is standard for incentive stock options, ensuring the director benefits only if the stock appreciates.
• A 3-year (36-month) vesting schedule is a common industry practice for director equity awards, promoting long-term commitment.

Corporate Governance

Related Party Transactions

• The options were granted to Sarah Reed, General Counsel of RA Capital Management, L.P., which is a 10% owner and has other representatives (Kolchinsky, Shah) on the board.
• Ms. Reed holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., with proceeds offsetting advisory fees owed to RA Capital Management, L.P. This constitutes an indirect benefit to the related parties.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a key director (affiliated with a major investor) with long-term shareholder value. Dilution from option exercise is a potential, but expected, consequence of equity compensation.

Next Steps

• The options will begin vesting in monthly installments starting September 8, 2025.
• Ms. Reed's continued service as a director is required for the options to vest.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a non-employee director, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Vor Biopharma Inc. or warrant a change in an existing position. Investors should continue to evaluate the company based on its operational performance, clinical pipeline, and broader market conditions.

Keywords

Vor Biopharma, VOR, RA Capital Management, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Biopharma